Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
38results about How to "Lower lung index" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Compounds having virus resistance and composition thereof
ActiveCN103211829ATherapeuticPreventiveOrganic active ingredientsAntiviralsHuman papillomavirusViral infectious disease
The invention discloses compounds having virus resistance and a composition thereof. The composition comprises one or more of the 13 compounds comprising 6'-O-caffeoyl deacetyl asperulosidic acid methyl ester. The compounds having virus resistance and the composition thereof can be extracted from plants and can also be prepared by synthesis. The composition comprising the compounds having virus resistance can prevent and treat viral infection-caused diseases such as influenza, myocarditis, conjunctivitis, viral pneumonia, encephalitis, leukemia, hepatitis B, hepatitis C, AIDS, genitourinary system infection, EB virus infection, human papillomavirus infection and cytomegalovirus infection. The composition can be prepared into an oral preparation, an injection, a spray, a subcutaneous injection and an anus suppository.
Owner:樊向德 +1
Dripping pills of 'Xiao Chaihu'
InactiveCN1569054AEnhance the efficacy of ingredientsReduce dosageMetabolism disorderDigestive systemPlant TubersGinger Rhizome
The invention provides a dripping pills of radix bupleuri and its preparing method, wherein the dripping pill comprises Bupleurum root, pinellia tuber, fresh ginger, pilose asiabell root, licorice root, baikal skullcap root, through the steps of extracting, adjusting pH, spray drying, mixing extracts, concentrating, and charging auxiliary materials.
Owner:TIANJIN TASLY PHARMA CO LTD
Application of Anerning granules in preparing medicament for treating viral pneumonia
InactiveCN103550596ALower lung indexProtect deathAntiviralsUnknown materialsCurative effectDeath cause
The invention discloses application of Anerning granules in preparing a medicament for treating viral pneumonia. The granules have a remarkable curative effect on viral pneumonia caused by respiratory syncytial virus and influenza virus, can be used for remarkably reducing the lung index, and is in dose-effect relationship. The Anerning granules can be used for protecting experimental animal death caused by respiratory syncytial virus (RSV), and has a remarkable inhibition effect on spleen index and thymus index reduction caused by RSV, can be used for reducing animal death cased by viral pneumonia, and can be used for remarkably protecting the immunity of experimental animals.
Owner:SHANDONG JINHE DRUG RES DEV
Traditional Chinese medicinal compound preparation for treating heart heat internal disturbance type night cry
ActiveCN104784372ANo inhibitory effectLower lung indexDrug compositionsPlant ingredientsSolventInsomnia
The invention discloses a traditional Chinese medicinal compound preparation for treating heart heat internal disturbance type night cry, and a preparation method and an application thereof. The preparation comprises, by weight, 2-40 parts of honeysuckle flower, 2-40 parts of Rhizoma Coptidis and 2-40 parts of common rush. Above components can be respectively extracted and then mixed, and can also be mixed and then extracted; an extraction solvent can be water or 10-95% ethanol; and an extraction method is a routine traditional Chinese medicine extraction method. The above medicinal composition prepared in the invention can be processed through routine methods to prepare various oral preparations used for treating heart heat internal disturbance type night cry. The traditional Chinese medicinal compound preparation for treating heart heat internal disturbance type night cry can clear heat and detoxify, and is used for reducing heart heat, dispelling fetal toxicity, dispel blood stasis, and treating upset, insomnia and children's night cry.
Owner:INST OF CHINESE MATERIA MEDICA CHINA ACAD OF CHINESE MEDICAL SCI
Tibetan medicine composition used for viral pneumonia
InactiveCN106913802AReduce mortalityLower lung indexAntiviralsRespiratory disorderInfluenza A (H5N1) VirusInfluenza A (H1N1) virus
The invention provides a Tibetan medicine composition used for viral pneumonia. Results of animal experiments show that high dose of the Tibetan medicine composition enables the inhibition rate of the lung index of a mouse with pneumonia caused by influenza A H1N1 viruses, influenza A H2N2 viruses, influenza A H5N1 viruses, influenza B viruses and respiratory syncytial viruses (RSVs) to be greater than 40%; the lung index of a model mouse having taken the composition has no significant difference compared with the lung index of a normal mouse from a control group; medium dose and low dose of the composition also have substantial inhibitory effect, with the inhibition rates both greater than 15%; the Tibetan medicine composition can substantially reduce the mortality of mice caused by infection with RSVs and substantially resist reduction in the spleen indexes and thymus indexes of mice infected with RSVs; and the Tibetan medicine composition can substantially improve the immunologic functions of mice with RSV viral pneumonia and reduce the mortality of the mice.
Owner:SHANDONG JINHE DRUG RES DEV
Application of soft capsule capable of clearing heat and eliminating toxin in preparation of medicament for treating viral pneumonia
ActiveCN102139051AInhibitory activityLower lung indexAntiviralsRespiratory disorderBaical Skullcap RootPneumonitis
The invention provides the application of a soft capsule capable of clearing heat and eliminating toxin in the preparation of a medicament for treating viral pneumonia, wherein the soft capsule capable of clearing heat and eliminating toxin comprises active components prepared from the following raw materials in parts by weight: 670 parts of gypsum, 134 parts of honeysuckle, 107 parts of figwort root, 80 parts of rehmannia root, 67 parts of forsythia, 67 parts of cape jasmine fruit, 67 parts of Chinese violet, 67 parts of baical skullcap root, 67 parts of Chinese gentian, 67 parts of indigowoad root, 54 parts of anemarrhena asphodeloides bunge and 54 parts of dwarf lilyturf tuber. Results of clinical tests of the soft capsule show that: when the soft capsule capable of clearing heat and eliminating toxin is adopted, pulmonary indexes can be reduced; and moreover, the soft capsule has an obvious inhibition effect on the mouse viral pneumonia caused by virus infection, and can be used for preparing the medicament for treating the viral pneumonia.
Owner:CSPC OUYI PHARM CO LTD
Application of radix bupleuri polysaccharide in preparing medicine for preventing and treating vaccinum influenzae vivum and virus pneumonia
InactiveCN105232573AStrong therapeutic effect on influenza virus-induced acute lung injuryThe role of acute lung injuryOrganic active ingredientsAntiviralsPulmonary edemaTherapeutic effect
The invention belongs to the field of traditional Chinese medicines, and in particularly relates to an application of radix bupleuri polysaccharide in preparing a medicine for preventing and treating flu and virus-induced acute lung injury. According to the invention, a total polysaccharide extract is separated and extracted from traditional Chinese medicine radix bupleuri, wherein the average yield of the product is 3%, and the content of polysaccharide exceeds 65%. The integral experiment proves that the radix bupleuri total polysaccharide extract has a remarkable treatment effect for the mouse acute lung injury induced by influenza A virus H3N2. Through an anti-inflammatory mechanism thereof, the radix bupleuri polysaccharide inhibits the release and activation of pro-inflammatory cytokines and chemotactic factors, promotes the release of the inflammatory cytokines, inhibits the replication of the virus, and alleviates empsyxis and pulmonary edema, thus reducing acute lung injury. The radix bupleuri polysaccharide can be used for preparing the medicine for preventing and treating vaccinum influenzae vivum and virus pneumonia.
Owner:FUDAN UNIV
Application of simiarenol
ActiveCN105943540ASignificant anti-upper respiratory infection effectLower lung indexAntibacterial agentsOrganic active ingredientsBacteroidesColony number
The invention provides an application of simiarenol in preparation of drugs for treatment of upper respiratory tract infection. Experiments prove that simiarenol has a certain inhibition effect on both respiratory tract infection related viruses and bacteria and also reduces the lung index, the TNF-alpha content, nasal mucosa inflammatory cell number and the nasopharyngeal lavage liquid colony number of mice with upper respiratory tract infection, and indicate that simiarenol has an obvious anti upper respiratory tract infection effect.
Owner:JIANGSU KANION PHARMA CO LTD
Use of 1-ethyl-3, 7-dimethylxanthine in preparing medicine for treating pneumonia
ActiveCN113546089ALower lung indexReduce the level of inflammatory cytokinesAntibacterial agentsOrganic active ingredientsInflammatory factorsWhite blood cell
The invention relates to use of 1-ethyl-3, 7-dimethylxanthine in preparing a medicine for treating pneumonia and belongs to the technical field of medicines. The invention provides use of 1-ethyl-3, 7-dimethylxanthine or a salt thereof in preparing a medicine for treating pneumonia. Pharmacological experiment results show that various dosage forms of the 1-ethyl-3, 7-dimethylxanthine can obviously inhibit pneumonia caused by infection of viruses, bacteria and mycoplasmas, reduce a lung index of infected mice, reduce levels of inflammatory factors such as TNF-alpha, IL-8, IL-10 and IL-17, improve a level of IFN-gamma and improve count of leukocyte and neutrophile granulocyte in peripheral blood, which indicate that the 1-ethyl-3, 7-dimethylxanthine has a strong anti-pneumonia effect.
Owner:WEST CHINA HOSPITAL SICHUAN UNIV +1
Application of alpha-L-fucosidase inhibitor in preparation of medicine for treating infantile pneumonia
InactiveCN111904959ALower lung indexReduce mortalityAntiviralsHeterocyclic compound active ingredientsViral pneumonitisPharmaceutical medicine
The invention provides application of an alpha-L-fucosidase inhibitor deoxyfuconojirimycin or pharmaceutically acceptable salt thereof in preparation of a medicine for preventing and / or treating infantile viral pneumonia. The deoxyfuconojirimycin or the pharmaceutically acceptable salt thereof can inhibit virus activity, reduce lung index of a subject, reduce death rate, prolong survival time, inhibit inflammatory factor generation and reduce IFN-gamma, TNF-alpha and IL-6 levels.
Owner:MUDANJIANG MEDICAL UNIV
Applications of rotundic acid in preparation of anti-influenza virus drugs
The present invention discloses applications of rotundic acid in preparation of anti-influenza virus drugs, further applications of rotundic acid in preparation of drugs for treatment of pneumonia caused by influenza viruses, wherein the influenza virus is preferably influenza A H1N1 virus. According to the present invention, the in vitro cell experiment results prove that the IC50 value of the rotundic acid on H1N1 influenza virus is 5.8 [mu]g / mL, and is comparable to the IC50 value of the positive drug ribavirin; and the mouse influenza model pharmacological experiment results prove that the rotundic acid can significantly reduce the lung index of influenza-infected mice, and shows a certain dose-effect characteristic on H1N1.
Owner:SUN YAT SEN UNIV
Application of sodium valproate in preparation of drug for treating human coronavirus infected pneumonia
PendingCN111671742AProtectiveReduce loadAntiviralsRespiratory disorderPulmonary infectionPharmaceutical formulation
The invention discloses an application of sodium valproate (VPA) in preparation of a drug for treating respiratory tract virus infectious diseases, and a pharmaceutical preparation containing the VPAand prepared according to the application. The preparation has remarkable prevention and treatment effects on primary and / or secondary pulmonary infection caused by infection of respiratory tract virus including novel coronavirus.
Owner:ACADEMY OF MILITARY MEDICAL SCI
Application of traditional Chinese medicine composition in preparation of medicine for treating viral pneumonia
InactiveCN111803588AInhibitory activityLower lung indexAntiviralsRespiratory disorderFritillaria thunbergiiInfluenza Viruses Type A
The invention discloses an application of a traditional Chinese medicine composition in preparation of a medicine for treating viral pneumonia. The traditional Chinese medicine composition is preparedfrom the following raw materials in parts by weight: 30 to 40 parts of radix pseudostellariae, 15 to 20 parts of thunberg fritillary bulb, 15 to 20 parts of radix trichosanthis, 5 to 15 parts of rhizoma bletillae, 5 to 10 parts of liquorice root and 5 to 15 parts of betel nut. The viral pneumonia is pneumonia caused by any one of an influenza A virus H1N1, an influenza A virus H2N2, an influenzaB virus and a novel coronavirus. The traditional Chinese medicine composition disclosed by the invention can obviously inhibit the activity of viruses in mice infected by the viral pneumonia; the lungindex inhibition rate is higher than 20%; and meanwhile, the traditional Chinese medicine composition can also be used for adjusting the Th1 / Th2 cell proportion in a viral pneumonia infected mouse body, and adjusting the protein expression quantity of inflammatory response related factors IL-4, IL-5, IgE and IFN-gamma and the content of oxidative stress related substances GSH, T-AOC, MDA and SOD.
Owner:武汉贝参药业股份有限公司
Antiviral traditional Chinese medicine composition for respiratory system
InactiveCN111514213ALower lung indexReduce mortalityAntibacterial agentsAntiviralsStreptococcus pneumoniae InfectionsOseltamivir
The invention relates to an antiviral traditional Chinese medicine composition for a respiratory system. The traditional Chinese medicine composition, namely an anti-inflammatory and antipyretic mixture, has a remarkable treatment effect on respiratory system infectious mouse models induced by influenza viruses, streptococcus pneumoniae and beta hemolytic streptococcus, has the effect equivalent to that of oseltamivir and amoxicillin under the clinical use dosage, and also provides a new thought for clinical treatment of novel coronavirus pneumonia. The invention adopts the technical scheme that the anti-inflammatory and antipyretic mixture is used for treating influenza virus H1N1 / FM1 strain infection, streptococcus pneumoniae infection and beta hemolytic streptococcus infection. The dosage of the anti-inflammatory and antipyretic mixture is 20mL / kg, 10mL / kg or 5mL / kg.
Owner:TSING HUA DE REN XIAN HAPPINESS PHARMA
Medical application of phillygenin
PendingCN113440510AGood treatment effectEffective in preventing pulmonary fibrosisRespiratory disorderHeterocyclic compound active ingredientsSide effectFibrosis
The invention discloses application of phillygenin to preparation of a medicine for preventing or treating pulmonary fibrosis, and belongs to the field of medicine. The phillygenin disclosed by the invention is a traditional Chinese medicine monomer extracted from the traditional Chinese medicine fructus forsythiae; and animal tests show that the phillygenin has a remarkable prevention and treatment effect on pulmonary fibrosis. The phillygenin has the advantages of exact curative effect of resisting pulmonary fibrosis, low side effect and wide medical application prospect.
Owner:LUNAN PHARMA GROUP CORPORATION
Application of Hedraaponin C in preparation of medicine for treating and preventing acute lung injury
PendingCN113318119AInhibition of activationLower lung indexAntibacterial agentsOrganic active ingredientsWhite blood cellNeutrophilic Myelocytes
The invention discloses application of Hedraaponin C in preparation of a medicine for treating and preventing acute lung injury. The structural formula of the Hedraaponin C is shown in formula (I). The Hedraaponin C has a certain protection effect on mouse ALI caused by LPS, the effect of the Hedraaponin C is not only through reducing release of TNF-alpha, IL-6 and IL-1beta, and reducing accumulation of neutrophils, lymphocytes and leukocytes in lung tissue, but also relates to inhibition of activation of a PIP2 signal channel, an NF-kappa B signal channel and an NLRP3 inflammasome.
Owner:GUANGXI XINHAI PHARM TECH CO LTD
Andrographolide derivative for resisting influenza virus infection and preparation method thereof
InactiveCN113173895ANovel structureLower lung indexOrganic chemistryAntiviralsOrganic solventChemical compound
The invention provides an anti-influenza virus andrographolide derivative and a preparation method thereof. The preparation method comprises the following steps: dissolving andrographolide in an organic solvent, and conducting esterifying with caffeic acid to obtain the andrographolide derivative with a novel structure. The novel compound, namely the andrographolide derivative can reduce the lung index of influenza virus-infected mice, and has an inhibition effect on influenza viruses; and with the novel compound, the lesion degrees of the lungs of the mice with influenza can be reduced, the lungs of the mice with influenza are obviously protected, and the survival rate of the mice is increased. The preparation method of the andrographolide derivative is simple, reaction conditions are easy to control, reproducibility is good, the utilization rate of raw materials is high, and the method is suitable for industrial production.
Owner:籍建亚
A new drug application of iridoid glycosides
ActiveCN104510747BReduce loadLower lung indexAntibacterial agentsOrganic active ingredientsViral MyocarditisAntibacterial agent
The invention belongs to the field of medicines and particularly relates to a new application of an iridoid glycoside compound, genipin-1-[beta]-D-gentiobioside, and a composition composed by compounding the genipin-1-[beta]-Dgentiobioside with other components as effective components for preparing antiviral drugs, antibacterial drugs, fever alleviating drugs, inflammation resistant drugs and anti-oxidizing drugs. The iridoid glycoside compound and the composition can be used for treating acute respiratory infection, flu, pneumonia, viral hepatitis type B, herpes zoster, herpes viral keratitis, viral myocarditis, Epstein-Barr virus infection, retrovirus infectious diseases and bacterial infectious diseases.
Owner:樊向德 +1
A preparation method of Shiqi exogenous preparation
ActiveCN104740118BLower lung indexSymptoms improvedAntiviralsRespiratory disorderBerchemia lineataAnti virus
The invention discloses a preparation method for a Shiqi exogenous preparation. The Shiqi exogenous preparation comprises the following raw materials: holly root, berchemia lineata, rose apple, fragrant glory-bower and pandanaceae pandanus tectorius. The preparation method is characterized by comprising the following steps: taking the raw materials, adding 50-80% of ethanol or water and carrying out low-temperature ultrasonic extraction for 5-6 times, filtering, combining filtrates, and carrying out low-temperature reduced pressure concentration. The invention further discloses an application of the Shiqi exogenous preparation prepared by the method in preparation of related anti-influenza virus medicines. The Shiqi exogenous preparation obtained by the preparation method disclosed by the invention has a better anti-virus activity.
Owner:中山市恒生药业有限公司
Applications of bear gall dropping pills in preparation of antibacterial drugs
PendingCN111000870AInhibits protein synthesisPrevent extensionAntibacterial agentsUnknown materialsStreptococcus pneumoniae InfectionsAntibiosis
The invention discloses applications of bear gall dropping pills in preparation of antibacterial drugs. According to the invention, the antibacterial pharmacodynamic activity of bear gall dropping pills is studied, and the experimental study of bear gall dropping pills on mouse infection models caused by staphylococcus aureus and streptococcus pneumoniae is carried out; and through the animal experiments on the influence of bear gall dropping pills on mouse staphylococcus aureus and streptococcus pneumoniae infection models, it is accidentally found that the bear gall dropping pills can prolong the survival time of animals, improve the survival rate of the animals, reduce the lung index and reduce the pulmonary lesion rate, so that the application prospect of the bear gall dropping pills in preparation of antibacterial drugs is revealed.
Owner:SHANGHAI KAIBAO PHARMA
Broad-spectrum antiviral traditional Chinese medicine volatile oil preparation and use thereof
ActiveCN113209185AGood treatment effectLower lung indexAntiviralsRespiratory disorderBiotechnologyHouttuynia
The invention discloses a broad-spectrum antiviral traditional Chinese medicine volatile oil preparation and use thereof. Effective components in eleven volatile oils, namely tea tree volatile oil, chimonanthus nitens volatile oil, thyme volatile oil, bay leaf volatile oil, eucalyptus robusta volatile oil, lemon volatile oil, houttuynia cordata volatile oil, myrtus communis volatile oil, ravensara volatile oil, cedrus atlantica volatile oil and folium artemisiae argyi volatile oil, are different from one another and have a synergistic effect. The broad-spectrum antiviral traditional Chinese medicine volatile oil preparation has a good treatment effect on diseases caused by different viruses, and can reduce the lung index, reduce the death rate and prolong the survival time. Tests prove that the provided traditional Chinese medicine volatile oil preparation has an obvious effect of reducing lung indexes of a mouse pneumonia model caused by hemagglutinating virus of Japan and a mouse pneumonia model caused by human coronavirus 229E.
Owner:江西古香今韵大健康产业有限公司
Lung clearing preparation for treating respiratory virus infection diseases
InactiveCN1287811CGood treatment effectExcellent anti-virusAntiviralsUnknown materialsDiseasePharmaceutical drug
The invention discloses a pharmaceutical preparation for clearing lung-heat which is prepared form Schizonepeta tenuifolia, honeysuckle flower, sweet wormwood, and artificial ox gallstone through the steps of sorting, rouging, watering and boiling,centrifugal filtrating, spray drying, dry method palletizing, spraying volatile oil, and charging cow-bezoar powder.
Owner:NANJING UNIVERSITY OF TRADITIONAL CHINESE MEDICINE
A kind of purposes of sago cuckoo alcohol
ActiveCN105943540BSignificant anti-upper respiratory infection effectLower lung indexAntibacterial agentsOrganic active ingredientsColony numberBacteroides
The invention provides an application of simiarenol in preparation of drugs for treatment of upper respiratory tract infection. Experiments prove that simiarenol has a certain inhibition effect on both respiratory tract infection related viruses and bacteria and also reduces the lung index, the TNF-alpha content, nasal mucosa inflammatory cell number and the nasopharyngeal lavage liquid colony number of mice with upper respiratory tract infection, and indicate that simiarenol has an obvious anti upper respiratory tract infection effect.
Owner:JIANGSU KANION PHARMA CO LTD
Pharmaceutical composition for treating pneumonia
ActiveCN113546083ALower lung indexReduce the level of inflammatory cytokinesAntibacterial agentsAntiviralsInflammatory factorsPharmaceutical drug
The invention relates to a pharmaceutical composition for treating pneumonia and belongs to the technical field of medicines. The provided pharmaceutical composition for treating pneumonia contains a compound A or a salt thereof and a compound B or a salt thereof. Pharmacological experiment results show that the pharmaceutical composition can significantly inhibit pneumonia caused by infection of viruses, bacteria, mycoplasmas and the like, reduce a lung index of infected mice, reduce inflammatory factors such as TNF-alpha, IL-8, IL-10 and IL-17, and improve a level of IFN-gamma, which indicates that the composition has a strong anti-pneumonia effect.
Owner:WEST CHINA HOSPITAL SICHUAN UNIV +1
Application of a pharmaceutical composition in the preparation of antiviral drugs
ActiveCN109078051BLower lung indexReduce fatalityAntiviralsRespiratory disorderBiotechnologyAntiviral drug
The invention provides an application of a pharmaceutical composition in the preparation of antiviral drugs, which belongs to the field of medicines. The medicinal composition is an extract obtained by mixing and extracting the fennel fennel and the thorn bean with a mass ratio of 1:0.2-5. The medicinal composition is a mixed extract of fennel fennel and thorn bean, has better antiviral effect, can be used for preparing antiviral medicine or medicine for upper respiratory tract infection, and has wide application prospect.
Owner:深圳市新鸿镁医疗器械有限公司
Application of bear gall dropping pills in preparation of antiviral drugs
PendingCN111012754AProlong survival timeImprove survival rateAntiviralsUnknown materialsAntiviral drugPharmaceutical drug
The invention discloses application of bear gall dropping pills in preparation of antiviral drugs. Through animal experiments on the influence of the bear gall dropping pill on a mouse influenza A virus infection model, the applicant accidentally finds that the bear gall dropping pill can prolong the survival time of animals, improve the survival rate of the animals, reduce the lung index and reduce the pulmonary lesion rate, so that the application prospect of the bear gall dropping pill in preparation of antiviral drugs is revealed.
Owner:SHANGHAI KAIBAO PHARMA
Application of basic acid in the preparation of anti-influenza virus drugs
ActiveCN107158005BLower lung indexOrganic active ingredientsAntiviralsInfluenza A (H1N1) virusPharmaceutical drug
The present invention discloses applications of rotundic acid in preparation of anti-influenza virus drugs, further applications of rotundic acid in preparation of drugs for treatment of pneumonia caused by influenza viruses, wherein the influenza virus is preferably influenza A H1N1 virus. According to the present invention, the in vitro cell experiment results prove that the IC50 value of the rotundic acid on H1N1 influenza virus is 5.8 [mu]g / mL, and is comparable to the IC50 value of the positive drug ribavirin; and the mouse influenza model pharmacological experiment results prove that the rotundic acid can significantly reduce the lung index of influenza-infected mice, and shows a certain dose-effect characteristic on H1N1.
Owner:SUN YAT SEN UNIV
Targeted immunosuppressant TCABCD55 for preventing and treating infectious inflammation
ActiveCN113801224AInhibition of activationImprove survival rateAntibacterial agentsPeptide/protein ingredientsIMMUNE SUPPRESSANTSSingle-Chain Antibodies
The invention discloses a single-chain antibody of a human anti-complement C3d molecule and a fusion protein of the single-chain antibody and a complement inhibitor CD55. The antibody and the fusion protein have excellent antigen binding activity, in-vitro inhibition experiments show that C3d-ScFv-CD55 has an obvious inhibition effect corresponding to a single effector molecule CD55, and the effect is realized by identifying that the C3d component in a complement activation region plays a complement inhibition role. The targeted complement inhibitor C3d-ScFv-CD55 is used for treating influenza / bacteria co-infected mice, the survival rate is obviously increased, lung lesions are obviously relieved, the targeted complement inhibition effect is obvious, and the targeted complement inhibitor C3d-ScFv-CD55 has an obvious treatment effect compared with the single effector molecule CD55, and it proves that the fusion protein provided by the invention has an excellent application prospect in preparation of drugs for treating influenza virus and bacteria co-infected pneumonia.
Owner:中国人民解放军疾病预防控制中心
Pharmaceutical composition capable of preventing and curing influenza A (H1N1)
InactiveCN103479918BLower lung indexReduce mortalityAntiviralsPlant ingredientsIllicium verumArctium lappa
The invention relates to a pharmaceutical composition capable of preventing and curing the influenza A (H1N1) and the application of the pharmaceutical composition. The pharmaceutical composition is prepared from the following traditional Chinese medicinal raw materials in parts by weight: 50-100 parts of cherry stones, 15-30 parts of arctium lappa, 15-30 parts of folium mori, 6-12 parts of illicium verum, 26-40 parts of light wheat, and 80-200 parts of mung beans. According to the pharmaceutical composition provided by the invention, lung index and death rate of mice used in an experiment and infected with influenza viruses can be obviously reduced, the mean survival time of the mice can be prolonged, and the pharmaceutical composition gains precious time for the follow-up treatment of patients infected with the influenza A (H1N1).
Owner:田光波
Drop pills of medical broth of small bupleurum root
Owner:TIANJIN TASLY PHARMA CO LTD
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com